Drug Database
Back to search

United States· US:76978-101_3b0b0981-a681-4c0c-91fb-b662277e92ad

ATZUMI

A dihydroergotamine product containing dihydroergotamine mesylate, registered in United States by Satsuma Pharmaceuticals, Inc.. The same ATC class is registered in 8 of our 19 countries.

ATC N02CA01US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedATZUMIATCN02CA01REGISTER NO.US:76978-101_3b0b0981…PACKS LISTED4CHECKEDJune 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about dihydroergotamine mesylateAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Dihydroergotamine is registered in 8 of 19 countries.

Countries holding a registration under ATC N02CA01 (dihydroergotamine), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 6 of them publish a price we can compare per daily dose
Search dihydroergotamine products by name

Dihydroergotamine · ATC N02CA01

8 / 19 countries

  • Belgiumprice
  • Canada
  • Finlandprice
  • Franceprice
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
DIHYDROERGOTAMINE MESYLATE
Manufacturer
Satsuma Pharmaceuticals, Inc.
Country
United States (US)
ATC code
N02CA01
ATC class
Dihydroergotamine
Defined daily dose
1 mg, N
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
June 26, 2026

Packs & prices · 4

  • ndc11
    76978-101-08
  • ndc11
    76978-101-11
  • ndc11
    7697810108
    8 BOTTLE, UNIT-DOSE in 1 CARTON (76978-101-08) / 1 POWDER in 1 BOTTLE, UNIT-DOSE
  • ndc11
    7697810111
    1 BOTTLE, UNIT-DOSE in 1 CARTON (76978-101-11) / 1 POWDER in 1 BOTTLE, UNIT-DOSE

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

178 interactions on record for dihydroergotamine.

Graded by severity as the source publishes them — 54 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check dihydroergotamine against other medicinesHow interaction checks work

Dihydroergotamine · interactions on record

178 records

  • 54 severe
  • 90 moderate
  • 1 minor
  • 17 info

Most severe, free to view

  • EpinephrineA01AD01severe
  • IsomethepteneA03AX10severe
  • FenfluramineA08AA02severe
  • DexfenfluramineA08AA04severe

16 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Dihydroergotamine in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All dihydroergotamine products

Authorised across Europe · EMA

The same active substance is authorised in 8 EEA countries. Names it is sold under:

  • Austria · Dihydergot, Migranal
  • Belgium · Diergo Spray
  • France · Diergospray
  • United Kingdom (Northern Ireland) · Migranal
  • Greece · Dihydergot
  • Italy · Diidergot, Dineza
  • Poland · Dihydroergotaminum Filofarm
  • Sweden · Orstanorm

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4a148987-50c9-43ef-8ea7-03424e3b4ffc
GET /v1/drugs/4a148987-50c9-43ef-8ea7-03424e3b4ffc?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "NASAL",
  "source": "ndc",
  "strength": "5.2",
  "substance": "DIHYDROERGOTAMINE MESYLATE",
  "productndc": "76978-101",
  "dosage_form": "POWDER",
  "dea_schedule": null,
  "strength_unit": "mg/1",
  "application_number": "NDA217901",
  "marketing_category": "NDA"
}
API referenceMCP serverPlans

See everything about dihydroergotamine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console